| All patients (n=60) | BRCA1 (n=3) | BRCA2 (n=25) | BRCAX (n=32) | P-value |
---|---|---|---|---|---|
AGE AT DIAGNOSIS | Â | Â | Â | Â | Â |
Median | 62.5 (30.1 - 85.6) | 65.6 (49.5-80.1) | 61 (31.0 - 85.7) | 63.2 (30.1 - 81.8) | Â |
<60 yoa | 26 (43.3%) | 1 (33.3%) | 11 (44.0%) | 14 (43.8%) | Â |
>60 yoa | 34 (56.7%) | 2 (66.6%) | 14 (56.0%) | 18 (56.3%) | NS |
DISEASE SPECIFIC MORTALITY | 35.0% | 33.3% | 40.0% | 31.3% | Â |
SIDE | Â | Â | Â | Â | Â |
Right | 36 (60.0%) | 1 (33.3%) | 17 (68.0%) | 18 (56.2%) | Â |
Left | 24 (40.0%) | 2 (66.7%) | 8 (32.0%) | 14 (43.8%) | NS |
Unifocal | 56 (93.3%) | 3 (100%) | 22 (88.0%) | 31 (96.9%) | Â |
Multifocal | 2 (3.3%) | 0 | 2 (8.0%) | 0 | Â |
Bilateral | 2 (3.3%) | 0 | 1 (4.0%) | 1 (3.1%) | NS |
HISTOLOGICAL SUBTYPE | Â | Â | Â | Â | Â |
Invasive Ductal Carcinoma - No special type | 46 (76.7%) | 2 (66.7%) | 18 (72%) | 28 (87.5%) | Â |
IDC with Micropapillary component | 8 (13.3%) | 0 | 6 (24%) | 2 (6.3%) | Â |
Invasive Papillary Carcinoma | 4 (6.7%) | 1 (33.3%) | 1 (4%) | 2 (6.3%) | Â |
Invasive Lobular Carcinoma | 2 (3.3%) | 0 | 0 | 2 (6.3%) | NS |
BRE GRADE | Â | Â | Â | Â | Â |
1 | 2 (3.3%) | 0 | 1 (4%) | 1 (3.1%) | Â |
2 | 31 (51.7%) | 0 | 12 (48%) | 19 (59.4%) | Â |
3 | 27 (45.0%) | 3 (100%) | 12 (48%) | 12 (37.5%) | NS |
ER STATUS (ALLRED 0-8) | Â | Â | Â | Â | Â |
0 | 1 (1.7%) | 0 | 0 | 1 (3.3%) | Â |
1-5. | 5 (8.6%) | 1 (33.3%) | 2 (8.0%) | 2 (6.7%) | Â |
6-8. | 52 (89.7%) | 2 (66.7%) | 23 (92.0%) | 27 (90.0%) | Â |
NA | 2 | 0 | 0 | 2 | NS |
PR STATUS (ALLRED 0-8) | Â | Â | Â | Â | Â |
0 | 5 (8.8%) | 0 | 1 (4%) | 4 (13.8%) | Â |
1-5. | 8 (14.0%) | 0 | 5 (20%) | 3 (10.3%) | Â |
6-8. | 44 (77.2%) | 3 (100%) | 19 (76%) | 22 (75.9%) | Â |
NA | 3 | 0 | 0 | 3 | NS |
HER2 | Â | Â | Â | Â | Â |
Amplification | 5 (9.1%) | 0 | 2 (8.3%) | 3 (10.7%) | Â |
Non-amplified | 50 (90.9%) | 3 (100%) | 22 (91.7%) | 25 (89.3%) | Â |
NA | 5 | 0 | 1 | 4 | NS |
PHENOTYPE | Â | Â | Â | Â | Â |
Basal | 1 (1.7%) | 0 | 0 | 1 (3.3%) | Â |
Luminal | 52 (89.7%) | 3 (100%) | 23 (92.0%) | 26 (86.7%) | Â |
HER2 | 5 (8.6%) | 0 | 2 (8.0%) | 3 (10.0%) | Â |
NA | 2 | 0 | 0 | 2 | NS |
TUMOUR SIZE | Â | Â | Â | Â | Â |
Median | 17mm (2-50mm) | 15mm (9-25mm) | 17mm (6-40mm) | 16 (2-50mm) | Â |
TUMOUR STAGE | Â | Â | Â | Â | Â |
T1a | 1 (1.7%) | 0 | 0 | 1 (3.1%) | Â |
T1b | 8 (13.3%) | 1 (33.3%) | 4 (16.0%) | 3 (9.4%) | Â |
T1c | 31 (51.7%) | 1 (33.3%) | 10 (40.0%) | 19 (59.4%) | Â |
T2 | 19 (31.7%) | 1 (33.3%) | 11 (44.0%) | 7 (21.9%) | Â |
T3 | 1 (1.7%) | 0 | 0 | 1 | NS |
LYMPHOVASCULAR INVASION | Â | Â | Â | Â | Â |
Absent | 32 (57.1%) | 2 (66.7%) | 14 (60.9%) | 16 (53.3%) | Â |
Present | 24 (42.9%) | 1 (33.3%) | 9 (39.1%) | 14 (46.7%) | Â |
NA | 4 | 0 | 2 | 2 | NS |
PERINEURAL INVASION | Â | Â | Â | Â | Â |
Absent | 31 (56.4%) | 3 (100%) | 12 (50.0%) | 16 (57.1%) | Â |
Present | 24 (43.6%) | 0 | 12 (50.0%) | 12 (42.9%) | Â |
NA | 5 | 0 | 1 | 4 | NS |
PAGET'S DISEASE OF NIPPLE | Â | Â | Â | Â | Â |
Absent | 44 (84.6%) | 2 (100%) | 19 (86.4%) | 23 (82.1%) | Â |
Present | 8 (15.4%) | 0 | 3 (13.6%) | 5 (17.9%) | Â |
NA | 8 | 1 | 3 | 4 | NS |
NODAL STATUS | Â | Â | Â | Â | Â |
Cases with nodes examined | 46 (76.7%) | 3 (100%) | 20 (80.0%) | 23 (71.9%) | Â |
Cases with positive nodes | 20 (43.4%) | 2 (66.7%) | 9 (45.0%) | 9 (39.1%) | NS |
Average numbers of nodes examined per case | 12.9 (1-30) | 16.3 (13-24) | 15.9 (1-30) | 10.1 (1-29) | Â |
NODAL STAGE | Â | Â | Â | Â | Â |
N0 | 26 (56.5%) | 1 (33.3%) | 11 (55.0%) | 14 (60.1%) | Â |
N1 | 18 (39.1%) | 2 (66.7%) | 8 (40.0%) | 8 (34.8%) | Â |
N2 | 2 (4.3%) | 0 | 1 (5.0%) | 1 (4.3%) | NS |
Cases with extranodal extension | 8 (17.4%) | 0 | 5 (25.0%) | 3 (13.0%) | NS |
MARGINS | Â | Â | Â | Â | Â |
Clear | 29 (48.3%) | 1 (33.3%) | 12 (48.0%) | 16 (50.0%) | Â |
Involved | 15 (25.0%) | 0 | 6 (24.0%) | 9 (28.1%) | Â |
Not assessable | 16 (26.7%) | 2 (66.7%) | 7 (28.0%) | 7 (21.9%) | NS |
DCIS | Â | Â | Â | Â | Â |
Absent | 14 (25.0%) | 0 | 7 (29.2%) | 7 (24.1%) | Â |
NA | 4 | 0 | 1 | 3 | Â |
Present | 42 (75.0%) | 3 (100%) | 17 (70.8%) | 22 (75.9%) | NS |
Nuclear Grade | Â | Â | Â | Â | Â |
Low | 2 (4.8%) | 0 | 2 (11.8%) | 0 | Â |
Intermediate | 26 (61.9%) | 1 (33.3%) | 10 (58.8%) | 15 (68.0%) | Â |
High | 14 (33.3%) | 2 (66.7%) | 5 (29.4%) | 7 (31.8%) | NS |